Previous 10 | Next 10 |
2024-04-16 09:15:50 ET Summary PFE's dividend has reached the sky-high (for a biotech) ~6% mark. Are the dividend and recent share price decline enough to make PFE an attractive play? PFE is following a similar trajectory to GILD in its post-HCV stagnation. PFE may be wort...
2024-04-12 10:46:47 ET More on iShares Russell 1000 Growth ETF: IWF ETF: Solid Track Record, But Looks Overextended Now Stocks with the least price swings, most attractive option-sale candidates - JPM 10 Attractive sell puts within the Russell 1000 - JPM Seek...
2024-04-12 05:11:48 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-04-11 13:51:45 ET More on iShares Russell 1000 Growth ETF: IWF ETF: Solid Track Record, But Looks Overextended Now Attractive call overwriting opportunities for Russell 1000 stocks - JPM The top stocks with selling pressure across the Russell universe - Jefferie...
2024-04-11 09:15:34 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – April 11, 2024 – USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 mill...
2024-04-10 12:50:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...
2024-04-09 10:03:48 ET More on Madrigal Pharmaceuticals Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly I...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s...
2024-04-06 06:49:00 ET Three Motley Fool contributors have dividends on their minds as the second quarter of 2024 begins. And they think they've found some no-brainer dividend stocks to buy in April. Here's why they like AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) ,...
2024-04-06 06:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The market’s ri...
News, Short Squeeze, Breakout and More Instantly...
– Analysis Comparing Real-World and Clinical Trial Data Show Yescarta ® Has Higher Manufacturing Success Rates and Improved T-Cell Performance, Respectively, in Second-Line vs. Third-Line+ Treatment of Large B-cell Lymphoma – – Encore Oral Present...
-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as th...
NORTHAMPTON, MA / ACCESSWIRE / May 9, 2024 / A 22-year-old college student who didn't feel well was treated at an urgent care facility in Baton Rouge, Louisiana and expected to recover soon. But when his symptoms worsened, he returned to the emergency department and was given a more thorough che...